Adjuvant Therapy in Renal Cell Carcinoma

Adjuvant therapy is treatment that is administered in addition to a primary or initial treatment. In the case of cancer, adjuvant therapy often refers to the follow-up treatment given to patients after they have undergone surgery to remove any detectable disease.

The main purpose of adjuvant therapy is to prevent the recurrence of the cancer and therefore reduce patient mortality and prolong survival.

Cancer recurrence often occurs because cancer cells still remain after the primary treatment has been performed or administered. Adjuvant therapy is therefore given in cases where all obvious disease appears to have been removed, to help reduce the likelihood of this occurring. Therapy given in cases where disease is known to be remaining is not technically adjuvant therapy.

The primary treatment in cases of stage I, II and III renal cell carcinoma is either partial or complete surgical removal of the kidney. This procedure is referred to as nephrectomy. For stage III cancer, this may also include removal of any lymph nodes the cancer has spread to. At present, no adjuvant therapies are known to improve patient outcome in renal cell carcinoma. The administration of adjuvant therapies after surgery such as chemotherapy, target therapy, radiotherapy or immunotherapy has so far not been shown to have beneficial effects after the cancer has been surgically removed. However, clinical trials exploring adjuvant therapies for kidney cancer are ongoing.

In the case of stage IV renal cell carcinoma that has spread or metastasized to other parts of the body, patients may still benefit from surgical removal of the tumor. Nephrectomy in these patients is often combined with an immunotherapy called interferon-alfa (IFN-alfa). Other therapies that may be used to treat these cancers include embolisation, targeted therapy, radiotherapy and immunotherapy. However, as the disease is known to still exist, these therapies are not considered adjuvant therapies.



Further Reading

Last Updated: Jun 16, 2023

Dr. Ananya Mandal

Written by

Dr. Ananya Mandal

Dr. Ananya Mandal is a doctor by profession, lecturer by vocation and a medical writer by passion. She specialized in Clinical Pharmacology after her bachelor's (MBBS). For her, health communication is not just writing complicated reviews for professionals but making medical knowledge understandable and available to the general public as well.


Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Mandal, Ananya. (2023, June 16). Adjuvant Therapy in Renal Cell Carcinoma. News-Medical. Retrieved on February 22, 2024 from

  • MLA

    Mandal, Ananya. "Adjuvant Therapy in Renal Cell Carcinoma". News-Medical. 22 February 2024. <>.

  • Chicago

    Mandal, Ananya. "Adjuvant Therapy in Renal Cell Carcinoma". News-Medical. (accessed February 22, 2024).

  • Harvard

    Mandal, Ananya. 2023. Adjuvant Therapy in Renal Cell Carcinoma. News-Medical, viewed 22 February 2024,


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.